Protagenic Therapeutics, Inc.\new Payments to Acquire Marketable Securities
Protagenic Therapeutics, Inc.\new (PTIX) reported Payments to Acquire Marketable Securities of $297.12 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2025-05-13
- Protagenic Therapeutics, Inc.\new payments to acquire marketable securities for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Protagenic Therapeutics, Inc.\new payments to acquire marketable securities for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Protagenic Therapeutics, Inc.\new payments to acquire marketable securities for the quarter ending 2024-06-30 was $0.00.
- Protagenic Therapeutics, Inc.\new payments to acquire marketable securities for the quarter ending 2024-03-31 was $297.12K.
- Protagenic Therapeutics, Inc.\new payments to acquire marketable securities for fiscal 2024 was $297.12K, a 89.25% decline from fiscal 2023.
- Protagenic Therapeutics, Inc.\new payments to acquire marketable securities for fiscal 2023 was $2.76M, a 8001.08% increase from fiscal 2022.
- Protagenic Therapeutics, Inc.\new payments to acquire marketable securities for fiscal 2022 was $34.12K, a 99.67% decline from fiscal 2021.
- Protagenic Therapeutics, Inc.\new payments to acquire marketable securities for fiscal 2021 was $10.40M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $0.00 derived: sum of 3 quarters · filed 2025-03-31 | $297.12K 10-K · filed 2025-03-31 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $297.12K 10-Q · filed 2024-11-14 | $3.05M derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-14 | $297.12K 10-Q · filed 2024-08-14 | $3.05M derived: sum of 3 quarters · filed 2025-05-13 | $3.06M derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-03-31 | $297.12K 10-Q · filed 2025-05-13 | $3.05M derived: sum of 2 quarters · filed 2025-05-13 | $3.06M derived: sum of 3 quarters · filed 2025-05-13 | $3.06M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $2.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $2.76M derived: sum of 2 quarters · filed 2025-03-31 | $2.76M derived: sum of 3 quarters · filed 2025-03-31 | $2.76M 10-K · filed 2025-03-31 |
| 2023-09-30 | $12.98K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $12.98K derived: sum of 2 quarters · filed 2024-11-14 | $12.98K 10-Q · filed 2024-11-14 | -$56.26K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | -$69.24K derived: sum of 3 quarters · filed 2024-05-14 | $34.12K derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-15 | -$69.24K derived: sum of 2 quarters · filed 2024-05-14 | $34.12K derived: sum of 3 quarters · filed 2024-05-14 | $34.12K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$69.24K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-05-14 | $34.12K derived: sum of 2 quarters · filed 2024-05-14 | $34.12K derived: sum of 3 quarters · filed 2024-05-14 | $34.12K 10-K/A · filed 2024-05-14 |
| 2022-09-30 | $103.36K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $103.36K derived: sum of 2 quarters · filed 2023-11-14 | $103.36K 10-Q · filed 2023-11-14 | $103.36K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | $0.00 derived: sum of 3 quarters · filed 2023-03-31 | |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-13 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $10.40M 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $10.40M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |